Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BALANCE-OBS: A Multiregional, Randomized, Multicenter, Active-Controlled Confirmatory Phase III Study to Evaluate the Efficacy and Safety of Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity

NCT07622810 is registered in ClinicalTrials.gov with Carnot Laboratories as lead sponsor.

NCT NCT07622810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07622810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BALANCE-OBS: A Multiregional, Randomized, Multicenter, Active-Controlled Confirmatory Phase III Study to Evaluate the Efficacy and Safety of Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
Lead sponsor
Carnot Laboratories
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2027
Enrollment
352 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

obesity & overweight